Petros Pharmaceuticals In... (PTPI)
0.13
-0.03 (-17.56%)
At close: Feb 20, 2025, 3:59 PM
0.13
0.08%
After-hours: Feb 20, 2025, 06:33 PM EST
undefined% (undefined)
| Bid | 0.13 |
| Market Cap | 1.47M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.8 |
| PE Ratio (ttm) | -0.03 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.13 |
| Volume | 15,891,087 |
| Avg. Volume (20D) | 4,761,132 |
| Open | 0.15 |
| Previous Close | 0.16 |
| Day's Range | 0.12 - 0.15 |
| 52-Week Range | 0.12 - 1.76 |
| Beta | undefined |
About PTPI
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vac...
Sector Healthcare
IPO Date Dec 2, 2020
Employees 21
Stock Exchange NASDAQ
Ticker Symbol PTPI
Website https://www.petrospharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for PTPI stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 2976.92% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 days ago
-53.48%
Petros Pharmaceuticals shares are trading lower af...
Unlock content with
Pro Subscription
1 month ago
+1.01%
Retros Pharmaceuticals shares are trading higher after the company announced it's in a position to lead the Rx-To-OTC switch market with its proprietary AI and quantum computing platform.
